• Revenues up 10.5% to $35.6 million
• Profit before tax up 48.1% to $21.9 million
• Cash reserves of $198.2 million, enabling self-financing expansion

Clinuvel Pharmaceuticals Ltd has reported strong financial results for the half year ended 31 December 2024. Revenues, including commercial and special access scheme sales as well as interest and other income, increased by 10.5% to $35.6 million. Expenses were well-controlled, rising by only 2% to $21.4 million, leading to a 48.1% increase in profit before tax to $21.9 million. Profit after tax grew by 28.7% to $14.1 million, and earnings per share increased by 27.4% to $0.28. The company's balance sheet remains robust, with cash reserves of $198.2 million as of 31 December 2024, up 7.8% from 30 June 2024. This strong cash position enables Clinuvel to self-finance its expansion plans, including the continued development of its melanocortin product pipeline and the global distribution of its lead product, SCENESSE, for the treatment of erythropoietic protoporphyria (EPP). Key achievements during the half year include growing commercial distribution of SCENESSE for EPP, advancing clinical studies for vitiligo, variegate porphyria, and DNA repair, and increasing the company's global visibility through industry events and investor engagement.